250 delegates representing leading biotech companies, global pharma organisations and internationally renowned academic institutions
55 presentations, case studies and panel discussions focused on the key issues in biomarker research, personalised healthcare and companion diagnostics
6 Interactive Streams:
- Biomarkers in Discovery & Preclinical Development
- Companion Diagnostics
- Biomarker Discovery & Verification
- Innovations In Biomarker Research
- Clinical Biomarkers
- Clinical Trials & Personalised Medicine
14 pre-scheduled one to one meetings, exhibition and informal networking opportunities
Oxford Global Conferences are proud to present the 9th Annual Biomarkers Congress, taking place on 25 & 26 February 2014 in Manchester.
The increasing interest in biomarker discovery in recent years has pushed biomarker research into the foreground of the modern pharmaceutical industry. New identification technologies have both widened the scope of biomarker research and underlined the need for robust validation, improved predictive value and the clear demonstration of clinical relevance.
The Biomarkers Congress will cover the latest advances in biomarker discovery and verification, including mass cytometry, selected reaction monitoring and chemical genetics. Our expert speakers will also discuss efforts to increase assay repeatability and specificity, informatics approaches to biomarker discovery and better sample management. In the Companion Diagnostics stream, presentations will cover emerging technologies, optimisation of existing platforms and strategies to improve strategic partnerships.
To build on the clinical case studies shared at last year’s event, we are pleased to introduce the co-located ‘Biomarkers in Clinical Development Congress’, focusing on the role of biomarkers in clinical decision making, drug efficacy prediction and clinical safety. Key decision makers in personalised medicine will complement these discussions with their insights into pharmacogenomics, stratification markers and precision medicine.